Overview

A Study to Assess the Bioequivalence of Fixed Dose Combination of HR20033 Relative to Co-administration of the Individual Components in Healthy Chinese Subjects

Status:
Not yet recruiting

Trial end date:
2021-12-10

Target enrollment:

Participant gender:

Summary

The trial is to assess the bioequivalence between HR20033 FDC tablet and co-administration of SHR3824 tablets and metformin XR tablets. The primary objective is to evaluate bioequivalence of SHR3824 and Metformin in healthy Chinese subjects in the fed state. The secondary objective is to evaluate the safety of HR20033 FDC tablet in healthy Chinese subjects.

Phase:

Phase 1

Details

Lead Sponsor:

Shandong Suncadia Medicine Co., Ltd.

Treatments:

Metformin